Michael Burgess actually said...

"I think there might be something that we can work on there."

"It is especially important that, as we evaluate this legislation, we consider the possibility of unintended consequences for both the patient and for the market."

"We must strike this delicate balance with the policies that we pass through this committee to ensure that they do not dampen the success or deter future investment in biomedical research and innovatio..."

"I fear that this policy could lead to a sort of public shaming of companies that are trying to benefit patients."